Apparent clearance of valproic acid in elderly epileptic patients: estimation of the confounding effect of albumin concentration

References

• Gertsner T, Bell N, Köning S. Oral valproic acid for epilepsy—long term experience in therapy and side effects. Expert Opin Pharmacother. 2008;9:285–92.
   PubMedGoogle Scholar
• Chateauvieux S, Morceau F, Dicato M, Diederich. Molecular and therapeutic potential and toxicity of valproic acid. J Biomed Biotechnol. 2010; 2010. pii: 479364.
   Google Scholar
• Bailey DN, Briggs JR. The binding of selected therapeutic drugs to human serum α-1 acid glycoprotein and human serum albumin in vitro. Ther Drug Monit. 2004;26:40–3.
   PubMed Web of Science ®Google Scholar
• Garnett WR, Anderson GD, Collins RJ. Antiepileptic drugs. In: Burton ME, Shaw LM, Schentang JJ, Evans WE, editors. Applied pharmacokinetics & pharmacodynamics. Principles of drug therapeutic monitoring. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2006. p. 491–511.
   Google Scholar
• Butler JM, Begg EJ. Free drug clearance in elderly people. Clin Pharmacokinet. 2008;47:297–321.
   PubMed Web of Science ®Google Scholar
• Perucca E, Berlowitz D, Birnbaum A, Cloyd JC, Garrard J, Hanlon JT, Pharmacological and clinical aspects of antiepileptic drug use in the elderly. Epilepsy Res. 2006;68S:S49–53.
   Google Scholar
• Bryson SM, Verma N, Scott PJW, Rubin PC. Pharmacokinetics of valproic acid in young and elderly subjects. Br J Clin Pharmacol. 1983;16:104–5.
   PubMed Web of Science ®Google Scholar
• Perucca E, Grimaldi R, Gatti G, Pirrachio S, Crema F, Frigo GM. Pharmacokinetics of valproic acid in the elderly. Br J Clin Pharmacol. 1984;17:665–9.
   PubMed Web of Science ®Google Scholar
• Birnbaum AK, Hardie NA, Conway JM, Bowers SE, Lackner TE, Graves NM, Valproic acid doses, concentrations, and clearances in elderly nursing home residents. Epilepsy Res. 2004;62:157–62.
   PubMedGoogle Scholar
• Fattore C, Mesina S, Battino D, Croci D, Mamoli D, Perucca E. The influence of old age and enzyme inducing comedication on the pharmacokinetics of valproic acid at steady-state: A case matched evaluation based on therapeutic drug monitoring data. Epilepsy Res. 2006;70:153–60.
   PubMed Web of Science ®Google Scholar
• Bauer LA, Davis R, Wilenski A, Raisys V, Levy RH. Valproic acid clearance: unbound fraction and diurnal variation in young and elderly adults. Clin Pharmacol Ther. 1985;37:697–700.
   PubMed Web of Science ®Google Scholar
• Winter ME. Basic clinical pharmacokinetics. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2004.
   Google Scholar
• Herbeth B. Albumine. In: Siest G, Henny J, Schiele F, editors, Références en Biologie Clinique. Amsterdam: Elsevier; 1990. p. 93–106.
   Google Scholar
• Hermida J, Tutor JC. A theoretical method for normalizing total serum valproic acid concentration in hypoalbuminemic patients. J Pharmacol Sci. 2005;97:489–93.
   PubMedGoogle Scholar
• Parent X, Marzullo C, Gutbub AM. Acide valproïque: estimation simple de la concentration sérique libre. Ann Biol Clin (Paris). 1993;51:649–50.
   PubMedGoogle Scholar
• Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, A simple noninvasive index can predict both fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518–26.
   PubMed Web of Science ®Google Scholar
• Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.
   PubMed Web of Science ®Google Scholar
• Shah V, Midha KK, Findlay JWA, Hill HM, Hulse JD, McGilveray IJ, Bioanalytical method validation. A revisit with a decade of progress. Pharm Res. 2000;17:1551–7.
   PubMedGoogle Scholar
• Bentué-Ferrer D, Tribut O, Verdier MC. Suivi thérapeutique pharmacologique du valproate. Thérapie. 2010;65:233–40.
   Google Scholar
• Fabris C, Smirne C, Toniutto P, Coletta C, Rapetti R, Minisini R, Assessment of liver fibrosis progression in patients with chronic hepatitis C and normal alanine aminotransferase values: The role of AST to platelet ratio index. Clin Biochem. 2006;39:339–43.
   PubMedGoogle Scholar
• Perucca E. Age-related changes in pharmacokinetics: predictability and assessment methods. Int Rev Neurobiol. 2007;81:183–99.
   PubMed Web of Science ®Google Scholar
• Dasgupta A. Usefulness of monitoring free (unbound) concentrations of therapeutic drugs in patient management. Clin Chim Acta. 2007;377:1–13.
   PubMed Web of Science ®Google Scholar
• Sproule B, Nava-Ocampo AA, Kapur B. Measuring unbound versus total valproate concentrations for therapeutic drug monitoring. Ther Drug Monit. 2006;28:714–15.
   PubMed Web of Science ®Google Scholar
• Brandt HM, Popish SJ, Lott RS. Effect of omega-3 fatty acids on valproate plasma protein binding. Ann Clin Psychiatr. 2010;22:280–2.
   PubMedGoogle Scholar
• Cloyd JC, Dutta S, Cao G, Walch JK, Collins SD, Granneman GR, Valproate unbound fraction and distribution volume following rapid infusions in patients with epilepsy. Epilepsy Res. 2003;53:19–27.
   PubMed Web of Science ®Google Scholar
• Ueshima S, Aiba T, Makita T, Nishimura S, Kitamura Y, Kurosaki Y, Characterization of non-linear relationship between total and unbound serum concentrations of valproic acid in epileptic children. Clin Pharm Ther. 2008;33:31–8.
   Google Scholar
• Gornall AG. Basic concepts in laboratory investigation. In: Gornall AG, editor. Applied biochemistry of clinical disorders. 2nd ed. Philadelphia: JB Lippincot Company; 1986. p. 3–13.
   Google Scholar
• Perucca E, Aldenkamp A, Tallis R, Krämer G. Role of valproate across the ages. Treatment of epilepsy in the elderly. Acta Neurol Scand. 2006;114 (Suppl 184):28–37.
   Google Scholar
• Verrotti A, Agostinelli S, Parisi P, Chiarelli F, Coppola G. Nonalcoholic fatty liver disease in adolescents receiving valproic acid. Epilepsy Behav. 2011;20:382–5.
   PubMedGoogle Scholar
• Luef G, Waldmann M, Sturm W, Naser A, Trinka E, Unterberger II, Valproate therapy and nonalcoholic fatty liver disease. Ann Neurol. 2004;55:729–32.
   PubMed Web of Science ®Google Scholar
• Luef G, Rauchenzauner M, Waldmann M, Sturm W, Sandhofer A, Seppi K, Non-alcoholic fatty liver disease (NAFLD), insulin resistance and lipid profile in antiepileptic drug treatment. Epilepsy Res. 2009;86:42–7.
   PubMed Web of Science ®Google Scholar
• Fisher CD, Lickteig AJ, Augustine LM, Ranger-Moore JR. Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of non-alcoholic fatty liver disease. Drug Metab Dispos. 2009;37:2087–94.
   PubMed Web of Science ®Google Scholar
• Goto S, Seo T, Hagiwara T, Ueda K, Yamauchi T, Nagata S, Potential relationship between transaminase abnormality and valproic acid clearance or serum carnitine concentrations in Japanese epileptic patients. J Pharm Pharmacol. 2008;60:262–72.
   Google Scholar
• Tan L, Yu JT, Sun YP, Ou JR, Song JH, Yu Y. The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients. Clin Neurol Neurosurg. 2010;112:320–3.
   PubMed Web of Science ®Google Scholar
• Lampon N, Tutor JC. A preliminary investigation on the possible association between diminished copper availability and non-alcoholic fatty liver disease in epileptic patients treated with valproic acid. Upsala J Med Sci. 2011;116:148–54.
   PubMed Web of Science ®Google Scholar
• Buechler C, Weiss TS. Does hepatic steatosis affect drug metabolizing enzymes in the liver? Curr Drug Metab. 2011;12:24–34.
   PubMed Web of Science ®Google Scholar